Genetic testing company specializing in exome and genome sequencing to diagnose rare pediatric and hereditary diseases.
Genetic testing company specializing in exome and genome sequencing to diagnose rare pediatric and hereditary diseases.
Is paid per test, mostly by insurers and Medicaid programmes, so payer coverage of exome and genome sequencing in children drives volume and price. It is the former Sema4, which narrowed to the GeneDx rare-disease unit and took its name in 2023.
Moat: narrow (data, IP / patents, scale). Large proprietary rare-disease genomic database improves diagnostic yield versus smaller testing labs.
Headquarters: Stamford, Connecticut · Founded: 2000 · Employees: 1,300
Size GeneDx (WGS) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.56B, the 1951st largest of 3,085 United States companies the cockpit tracks. Shares closed at $51.96 on 18 Nov 2026.
Performance Over six months the shares gained 16.2%, against +14.9% for the median peer and -2.2% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 14.6% over the last twelve months (peer median +9.2%); the operating margin is -13.7% (peer median 4.7%).
Valuation It trades at 54.2× forward earnings against a peer median of 29.9× (3rd most expensive of 16).
Capital Return on invested capital runs 31.2 points below its cost of capital (14.0% WACC).
Short interest Short interest is 22.0% of the free float (30 Oct 2026).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $461M | $428M | $305M | $203M | $235M |
| Revenue growth | — | +40% | +51% | -14% | — |
| Gross profit | $300M | $278M | $176M | $60.6M | -$54.7M |
| EBITDA | -$35.9M | $13.4M | $492,000 | -$128M | -$355M |
| Net income | -$111M | -$21.0M | -$52.3M | -$176M | -$549M |
| Free cash flow | -$101M | $14.3M | -$34.0M | -$185M | -$326M |
| Capital expenditure | $26.1M | $19.0M | $5.49M | $5.71M | $14.3M |
| Total debt | $215M | $113M | $117M | $120M | $77.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| GeneDx WGS | $1.56B | +16% | +15% | -14% | 54.2× | n/a |
| Natera NTRA | $42.0B | +41% | +37% | -9% | n/a | n/a |
| Labcorp LH | $30.1B | +44% | +6% | 11% | 19.3× | 14.5% |
| Quest Diagnostics DGX | $28.6B | +34% | +9% | 15% | 22.4× | 7.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | WGS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.4% | +1.3% | lowest of 21 |
| 6-month return | +16.2% | +14.9% | 11th highest of 21 |
| Distance from 52-week high | -69.6% | -22.4% | 2nd lowest of 21 |
| Revenue growth (TTM) | +14.6% | +9.2% | 8th highest of 21 |
| Operating margin | -13.7% | 4.7% | 3rd lowest of 21 |
| Forward P/E | 54.2× | 29.9× | 3rd most expensive of 16 |
| ROIC minus cost of capital | -31.2 pp | -4.1 pp | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 77.1× | 43.0% | +26.9% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| NeoGenomics NEO | United States | $1.98B | +72% | +11% | -6% | 53.5× | n/a | n/a |